Barclays Lowers Iqvia (NYSE:IQV) Price Target to $166.00

Iqvia (NYSE:IQV) had its target price cut by equities researchers at Barclays from $192.00 to $166.00 in a research report issued on Thursday, BenzingaRatingsTable reports. The firm currently has an “overweight” rating on the medical research company’s stock. Barclays‘s price target points to a potential upside of 50.17% from the company’s current price.

Several other research firms have also recently commented on IQV. Cfra cut their target price on Iqvia from $185.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday. Citigroup boosted their target price on Iqvia from $185.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Piper Sandler boosted their target price on Iqvia from to in a research note on Thursday, February 13th. JPMorgan Chase & Co. boosted their target price on Iqvia from $180.00 to $195.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Finally, SunTrust Banks cut their target price on Iqvia from $184.00 to $128.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Two investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Iqvia currently has an average rating of “Buy” and an average target price of $169.06.

NYSE IQV traded up $5.66 during trading on Thursday, hitting $110.54. The stock had a trading volume of 102,256 shares, compared to its average volume of 2,813,541. The company has a market capitalization of $18.64 billion, a PE ratio of 113.08, a P/E/G ratio of 1.05 and a beta of 0.94. The company’s 50-day moving average price is $138.81 and its two-hundred day moving average price is $147.25. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.05 and a current ratio of 1.05. Iqvia has a 12 month low of $81.79 and a 12 month high of $169.14.

Iqvia (NYSE:IQV) last released its earnings results on Wednesday, February 12th. The medical research company reported $1.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.02. The firm had revenue of $2.90 billion for the quarter, compared to analysts’ expectations of $2.85 billion. Iqvia had a return on equity of 17.65% and a net margin of 1.72%. The business’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.50 EPS. As a group, equities analysts anticipate that Iqvia will post 6.62 earnings per share for the current fiscal year.

In related news, CFO Michael R. Mcdonnell sold 12,000 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $155.07, for a total value of $1,860,840.00. Following the sale, the chief financial officer now owns 14,366 shares in the company, valued at approximately $2,227,735.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael J. Evanisko sold 6,250 shares of the stock in a transaction on Friday, January 10th. The shares were sold at an average price of $160.08, for a total value of $1,000,500.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 740,828 shares of company stock worth $121,469,155. Company insiders own 6.00% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp raised its stake in Iqvia by 6.2% in the 4th quarter. State Street Corp now owns 7,793,197 shares of the medical research company’s stock valued at $1,204,127,000 after acquiring an additional 454,619 shares during the period. Janus Henderson Group PLC raised its stake in Iqvia by 11.9% in the 4th quarter. Janus Henderson Group PLC now owns 4,140,062 shares of the medical research company’s stock valued at $639,680,000 after acquiring an additional 439,882 shares during the period. Alliancebernstein L.P. raised its stake in Iqvia by 14.9% in the 4th quarter. Alliancebernstein L.P. now owns 3,928,236 shares of the medical research company’s stock valued at $606,952,000 after acquiring an additional 508,606 shares during the period. Geode Capital Management LLC raised its stake in Iqvia by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 2,763,945 shares of the medical research company’s stock valued at $426,188,000 after acquiring an additional 32,424 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in Iqvia by 110.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,168,525 shares of the medical research company’s stock valued at $335,059,000 after acquiring an additional 1,136,399 shares during the period. Institutional investors and hedge funds own 89.25% of the company’s stock.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Story: Consumer Price Index (CPI)

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.